Try GOLD - Free
Can India Reclaim API Throne from China?
Bio Spectrum
|September 2024
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).
-
India is the source of around 60,000 generic brands across 60 therapeutic categories and manufactures more than 500 different APIs. However, India imports about 70 per cent of its APIs from China as it's a cheaper option than manufacturing them domestically. There were 58 APIs in which India was heavily dependent on China. In the case of 45 APIs, India was dependent on China for 100 per cent of imports. Out of these 58 APIs, 29 APIs are manufactured through fermentation and 29 APIs are manufactured through chemical synthesis. The Department of Pharmaceuticals has drawn up a list of 56 APIs to prioritise them for the Make-in-India initiative. These include APIs or bulk drugs that go into the making of essential drugs, such as antibiotics, anti-HIV medicines, and the humble but indispensable paracetamol. The plan to make APIs in India has been in the works for some time but the Council of Scientific and Industrial Research (CSIR was engaged only recently. Let's see how these steps taken by the government help to promote the production of KSMS and APIs in India in the coming years.
This story is from the September 2024 edition of Bio Spectrum.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Bio Spectrum
Bio Spectrum
Building Breakthrough Medical Devices
Dr Ria Khurana founded RNT Health Insights, a Chandigarh-based healthtech startup specialising in Al-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures, in 2022 along with Dr Tanmaya Gulati.
2 mins
January 2026
Bio Spectrum
Bridging classical epidemiology with modern science
A physician scientist with a MBBS from Lady Hardinge Medical College, (University of Delhi), a post-graduation in Paediatrics and a PhD from All India Institute of Medical Sciences (AIIMS), New Delhi, Prof.Shinjini Bhatnagar served as Professor of Eminence at Translational Health Science and Technology Institute (THSTI) until February 2023 and was subsequently appointed Distinguished Professor at THSTI until May 2025.
2 mins
January 2026
Bio Spectrum
"AI, Automation & Analytics: A new era of modern microbiology testing!"
Pharmaceutical manufacturing is undergoing a paradigm shift.
4 mins
January 2026
Bio Spectrum
The CRISPR Moment
CRISPR (clustered regularly interspaced short palindromic repeats) technology is ushering in a new era of gene and cell therapy, offering more precision and potential for treating genetic disorders, cancer, and infectious diseases.
2 mins
January 2026
Bio Spectrum
Leveraging Microfluidic Technology for mRNA-LNP Manufacturing
Over the past five years, messenger RNA (mRNA) therapeutics have evolved from experimental concepts into lifesaving medicines.
2 mins
January 2026
Bio Spectrum
Demonstrating India's Vaccine Capabilities
Havisure is India's first and only indigenously developed Hepatitis A vaccine, to address one of the country's most persistent public health challengeswidespread Hepatitis A infections caused by inadequate sanitation and contaminated food and water.
2 mins
January 2026
Bio Spectrum
Inspiring Future Generations
A PhD in molecular biology from the University of Cambridge, UK, Prof. Gaiti Hasan is a Distinguished Fellow at the National Centre for Biological Sciences (NCBS), Bengaluru.
2 mins
January 2026
Bio Spectrum
A Landmark for India's Antibiotic Innovation
After three decades of research and hard work, India has led the way with the creation of Nafithromycin, the country's first indigenous antibiotic.
2 mins
January 2026
Bio Spectrum
"Future vaccine innovation will be integration of R&D, regulatory support and manufacturing”
TechInvention Lifecare Limited, a vaccine focused biotechnology company headquartered in Mumbai, is recognised for its innovative contributions to global healthcare.
4 mins
January 2026
Bio Spectrum
Telangana: Building India's Most Credible Life Sciences Ecosystem
Telangana's recognition as BioSpectrum India's Best Performing State in Life Sciences 2025 is a timely validation of the direction the state has taken in recent years-one anchored in execution, responsiveness, and a clear understanding of where global life sciences value chains are headed.
4 mins
January 2026
Listen
Translate
Change font size

